Novartis’ bid to boost Entresto sales beyond $5 billion gets FDA panel lift
December 16, 2020 ZURICH (Reuters) – Novartis’ bid to pump up sales of its Entresto heart failure medicine beyond $5 billion annually got a boost when a U.S. Food and Drug advisory panel recommended it be used to treat a different form of the disease. Entresto, with more than $1.7 billion in sales last year, …
Novartis’ bid to boost Entresto sales beyond $5 billion gets FDA panel lift Read More »